Table 3. Classification of implementation outcomes by EBI (N = 183, n = 93) [28, 30, 31, 35, 36, 40, 42, 43, 45, 46, 48–51, 53–58, 60–64, 66–69, 71, 72, 74, 77–80, 83–94, 96, 97, 99–101, 103, 104, 106–109, 111–114, 116–145].

Type of Intervention	Regular HIV Testing for At Risk Groups (N = 8)	Rapid Access to Testing Services (N = 63)	Rapid ART Intervention (N = 0)	One-Stop Shop Model (N = 0)	Emergency Advice Service (N = 0)	Access to Mental Health Services (N = 3)	Role of the Pharmacist (N = 7)	Role of the Care Navigators (N = 56)	Individualised Plan of Care (N = 21)	Structured Follow-up (n = 21)	Diagnosis and Management of Co-infections (N = 1)	Diagnosis and Management of Comorbidities (N = 3)
Implementation outcome	The proportion of EBIs assessed per implementation outcomes (N)†
Acceptability (N = 100)	7	48	0	0	0	2	5	22	5	8	0	3
Adoption (N = 16)	0	11	0	0	0	0	1	3	1	0	0	0
Appropriateness (N = 3)	0	1	0	0	0	0	1	1	0	0	0	0
Feasibility (N = 35)	1	13	0	0	0	2	0	11	3	5	0	0
Fidelity (N = 16)	0	4	0	0	0	0	0	5	2	4	0	1
Implementation costs (N = 55)	0	8	0	0	0	0	1	24	12	9	1	0
Penetration (N = 2)	0	0	0	0	0	0	0	1	1	0	0	0
Sustainability (N = 15)	2	6	0	0	0	0	0	5	1	0	0	1

N represents the total number of EBIs that are evaluated on implementation. n represents the number of publications in which these EBIs are evaluated.

^†The numbers reported in the table do not add up to the total number of EBIs evaluated on implementation outcomes (N = 183) as EBIs could be evaluated on more than one implementation outcome.

ART, antiretroviral therapy; EBI, evidence-based intervention; HIV, human immunodeficiency virus.